Pharma Reviews: Net loss of 11 Sensex heavyweights higher than net profit of 16 bluechips

The Indian banking sector struggled to avert the rising NPAs; while the pharmaceutical industry faced regulatory actions by the US and EU regulators.
Read more: Net loss of 11 Sensex heavyweights higher than net profit of 16 bluechips